Accompanying therapy in oncohematological patients with secondary immunodeficiency

Actuality. The inability of a persons immune system to withstand foreign antigenic aggression is called immunodeficiency. More than 1/2 of all cases of secondary immunodeficiency (SID) in the world are occupied by hemoblastosis and, in a greater degree, the therapy, accompanied by the immunosuppress...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lali G. Babicheva, Irina V. Poddubnaya
Formato:	article
Lenguaje:	RU
Publicado:	IP Habib O.N. 2020
Materias:	secondary immunodeficiency hypogammaglobulimenia privigen intravenous immunoglobulin Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/9a65ffe348f149f987d8d324d766a5b1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9a65ffe348f149f987d8d324d766a5b1
record_format	dspace
spelling	oai:doaj.org-article:9a65ffe348f149f987d8d324d766a5b12021-11-30T17:03:34ZAccompanying therapy in oncohematological patients with secondary immunodeficiency1815-14341815-144210.26442/18151434.2020.2.200127https://doaj.org/article/9a65ffe348f149f987d8d324d766a5b12020-07-01T00:00:00Zhttps://modernonco.orscience.ru/1815-1434/article/viewFile/34957/23374https://doaj.org/toc/1815-1434https://doaj.org/toc/1815-1442Actuality. The inability of a persons immune system to withstand foreign antigenic aggression is called immunodeficiency. More than 1/2 of all cases of secondary immunodeficiency (SID) in the world are occupied by hemoblastosis and, in a greater degree, the therapy, accompanied by the immunosuppression. Due to the expansion of the arsenal of new targeted drugs for the treatment of oncohematological diseases affecting different parts of the immune system, to increasingly frequent use of autologous and especially allogeneic hematopoietic cell transplantation, the prevalence and the frequency of SID are inexorably increasing. Timely diagnosis of SID should be the starting point of the management of oncohematological patients to reduce the incidence of infectious complications and, as a result, case fatality rate. Monitoring is based on assessing risk factors and identifying the category of patients requiring active preventive measures before they develop severe infection. Elimination of the main cause of SID development is the preferred option for the prevention of the infectious complications. However, in case of multiple myeloma, chronic lymphocytic leukemia and other oncohematological diseases, this option is often impossible. Therefore, active accompanying therapy is necessary for this category of patients, in particular immunoglobulin (Ig) replacement therapy. Main clinical communities are currently in the process of updating their guidelines and recommendations on using Ig replacement therapy in patients with hemoblastosis accompanied severe recurrent infections; after ineffective antibiotic treatment; with a proven inadequate specific antibody response; IgG4 g/l. Numerous cohort, observational and randomized trials showed the significant reduction in the number of infectious complications in oncohematological patients on using long-term (not less than 1012 months) intravenous Ig replacement therapy. The lack of attention of oncologists and hematologists to the early diagnosis and prevention of these conditions leads to the increase in the number of infectious complications with all the consequences such as worsen treatment results and increase mortality among oncohematological patients. Conclusion. There is a real need to raise awareness among physicians and patients, to use screening and better management of the group of patients with increased risk of SID, and preventive use of intravenous Ig to reduce the incidence of infectious complications and active accompanying therapy aimed at reducing infection-related mortality.Lali G. BabichevaIrina V. PoddubnayaIP Habib O.N.articlesecondary immunodeficiencyhypogammaglobulimeniaprivigenintravenous immunoglobulinNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282RUСовременная онкология, Vol 22, Iss 2, Pp 89-97 (2020)
institution	DOAJ
collection	DOAJ
language	RU
topic	secondary immunodeficiency hypogammaglobulimenia privigen intravenous immunoglobulin Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	secondary immunodeficiency hypogammaglobulimenia privigen intravenous immunoglobulin Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Lali G. Babicheva Irina V. Poddubnaya Accompanying therapy in oncohematological patients with secondary immunodeficiency
description	Actuality. The inability of a persons immune system to withstand foreign antigenic aggression is called immunodeficiency. More than 1/2 of all cases of secondary immunodeficiency (SID) in the world are occupied by hemoblastosis and, in a greater degree, the therapy, accompanied by the immunosuppression. Due to the expansion of the arsenal of new targeted drugs for the treatment of oncohematological diseases affecting different parts of the immune system, to increasingly frequent use of autologous and especially allogeneic hematopoietic cell transplantation, the prevalence and the frequency of SID are inexorably increasing. Timely diagnosis of SID should be the starting point of the management of oncohematological patients to reduce the incidence of infectious complications and, as a result, case fatality rate. Monitoring is based on assessing risk factors and identifying the category of patients requiring active preventive measures before they develop severe infection. Elimination of the main cause of SID development is the preferred option for the prevention of the infectious complications. However, in case of multiple myeloma, chronic lymphocytic leukemia and other oncohematological diseases, this option is often impossible. Therefore, active accompanying therapy is necessary for this category of patients, in particular immunoglobulin (Ig) replacement therapy. Main clinical communities are currently in the process of updating their guidelines and recommendations on using Ig replacement therapy in patients with hemoblastosis accompanied severe recurrent infections; after ineffective antibiotic treatment; with a proven inadequate specific antibody response; IgG4 g/l. Numerous cohort, observational and randomized trials showed the significant reduction in the number of infectious complications in oncohematological patients on using long-term (not less than 1012 months) intravenous Ig replacement therapy. The lack of attention of oncologists and hematologists to the early diagnosis and prevention of these conditions leads to the increase in the number of infectious complications with all the consequences such as worsen treatment results and increase mortality among oncohematological patients. Conclusion. There is a real need to raise awareness among physicians and patients, to use screening and better management of the group of patients with increased risk of SID, and preventive use of intravenous Ig to reduce the incidence of infectious complications and active accompanying therapy aimed at reducing infection-related mortality.
format	article
author	Lali G. Babicheva Irina V. Poddubnaya
author_facet	Lali G. Babicheva Irina V. Poddubnaya
author_sort	Lali G. Babicheva
title	Accompanying therapy in oncohematological patients with secondary immunodeficiency
title_short	Accompanying therapy in oncohematological patients with secondary immunodeficiency
title_full	Accompanying therapy in oncohematological patients with secondary immunodeficiency
title_fullStr	Accompanying therapy in oncohematological patients with secondary immunodeficiency
title_full_unstemmed	Accompanying therapy in oncohematological patients with secondary immunodeficiency
title_sort	accompanying therapy in oncohematological patients with secondary immunodeficiency
publisher	IP Habib O.N.
publishDate	2020
url	https://doaj.org/article/9a65ffe348f149f987d8d324d766a5b1
work_keys_str_mv	AT laligbabicheva accompanyingtherapyinoncohematologicalpatientswithsecondaryimmunodeficiency AT irinavpoddubnaya accompanyingtherapyinoncohematologicalpatientswithsecondaryimmunodeficiency
_version_	1718406396633939968

Accompanying therapy in oncohematological patients with secondary immunodeficiency

Ejemplares similares